[{"orgOrder":0,"company":"Sitala Bio","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"FXS6837","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Sitala Bio","amount2":0.67000000000000004,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.67000000000000004,"dosageForm":"Undisclosed","sponsorNew":"Sitala Bio \/ Sitala Bio","highestDevelopmentStatusID":"8","companyTruncated":"Sitala Bio \/ Sitala Bio"}]

Find Clinical Drug Pipeline Developments & Deals by Sitala Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Under the licensing agreement, Sitala will hold the right of FXS6837, which is being evaluated for the treatment of immune disease.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : $25.0 million

                          August 26, 2025

                          Lead Product(s) : FXS6837

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Recipient : Fosun Pharmaceutical

                          Deal Size : $670.0 million

                          Deal Type : Licensing Agreement

                          blank